About Xencor (NASDAQ:XNCR)
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug, that in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; and AMG424, a bispecific CD38 x CD3 preclinical candidate for various myeloma. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104, which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. to develop and commercialize bispecific and other Fc engineered antibody drug candidates using its proprietary XmAb technologies and drug candidates, as well as MorphoSys Ag to develop and commercialize bispecific antibody product candidates; license agreement with Amgen Inc. to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc.was founded in 1997 and is headquartered in Monrovia, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XNCR
CUSIPN/A
Phone626-305-5900
Debt
Debt-to-Equity RatioN/A
Current Ratio6.41
Quick Ratio6.41
Price-To-Earnings
Trailing P/E Ratio-38.27
Forward P/E Ratio-17.24
P/E GrowthN/A
Sales & Book Value
Annual Sales$35.71 million
Price / Sales62.59
Cash FlowN/A
Price / CashN/A
Book Value$6.01 per share
Price / Book6.69
Profitability
EPS (Most Recent Fiscal Year)($1.05)
Net Income$-48,920,000.00
Net Margins-137.35%
Return on Equity-18.07%
Return on Assets-14.04%
Miscellaneous
Employees114
Outstanding Shares55,630,000
Xencor (NASDAQ:XNCR) Frequently Asked Questions
What is Xencor's stock symbol?
Xencor trades on the NASDAQ under the ticker symbol "XNCR."
How were Xencor's earnings last quarter?
Xencor Inc (NASDAQ:XNCR) released its quarterly earnings results on Monday, May, 7th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.16. Xencor had a negative return on equity of 18.07% and a negative net margin of 137.35%. View Xencor's Earnings History.
What price target have analysts set for XNCR?
7 Wall Street analysts have issued twelve-month price objectives for Xencor's shares. Their forecasts range from $28.00 to $56.00. On average, they expect Xencor's stock price to reach $38.4286 in the next year. View Analyst Ratings for Xencor.
What are Wall Street analysts saying about Xencor stock?
Here are some recent quotes from research analysts about Xencor stock:
- 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (5/11/2018)
- 2. Cantor Fitzgerald analysts commented, "XmAb5871 likely the asset of greatest interest in 2018. The B cell-targeting MAb is being tested in patients with IgG4 related disease (IgG4-RD) and in patients with systemic lupus erythematosus (SLE) with Phase 3 testing for the former expected to start in 2Q18 and data from Phase 2 testing for the latter expected in 4Q18. Because the MAb modulates B cell activity but does not eliminate them, we believe the safety profile could be regarded to be superior as compared with other therapies, e.g., Rituxan." (3/29/2018)
Who are some of Xencor's key competitors?
Some companies that are related to Xencor include Genmab A/S (GNMSF), Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM) and Madrigal Pharmaceuticals (MDGL).
Who are Xencor's key executives?
Xencor's management team includes the folowing people:
- Dr. Bassil I. Dahiyat Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 48)
- Mr. John J. Kuch, VP of Fin. & Sec. (Age 59)
- Dr. John R. Desjarlais Ph.D., Chief Scientific Officer and Sr. VP of Research (Age 54)
- Dr. Edgardo Baracchini Jr., Ph.D., M.B.A., Chief Bus. Officer (Age 59)
- Dr. Paul A. Foster M.D., F.A.H.A., Chief Medical Officer and Sr. VP (Age 64)
Has Xencor been receiving favorable news coverage?
Press coverage about XNCR stock has been trending positive on Monday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Xencor earned a news impact score of 0.27 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 47.97 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Xencor's major shareholders?
Xencor's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (5.76%), BlackRock Inc. (5.61%), BVF Inc. IL (1.62%), First Light Asset Management LLC (1.25%), Franklin Resources Inc. (1.04%) and Northern Trust Corp (0.86%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.
Which institutional investors are selling Xencor stock?
XNCR stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Lord Abbett & CO. LLC, Virginia Retirement Systems ET AL, GSA Capital Partners LLP, JPMorgan Chase & Co., Russell Investments Group Ltd., Millennium Management LLC and Atlantic Trust Group LLC. Company insiders that have sold Xencor company stock in the last year include Bassil I Dahiyat, Edgardo Baracchini Jr, John J Kuch and Paul A Foster. View Insider Buying and Selling for Xencor.
Which institutional investors are buying Xencor stock?
XNCR stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, BVF Inc. IL, PointState Capital LP, Artal Group S.A., Farallon Capital Management LLC, Citadel Advisors LLC, First Light Asset Management LLC and Prudential Financial Inc.. View Insider Buying and Selling for Xencor.
How do I buy shares of Xencor?
Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xencor's stock price today?
One share of XNCR stock can currently be purchased for approximately $40.18.
How big of a company is Xencor?
Xencor has a market capitalization of $2.24 billion and generates $35.71 million in revenue each year. The biopharmaceutical company earns $-48,920,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Xencor employs 114 workers across the globe.
How can I contact Xencor?
Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]
MarketBeat Community Rating for Xencor (XNCR)
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
